Course Content
Zambian Paediatric & Obstetrics-Gynecology (OB/GYN) Clinical Mastery

Haemophilia 

Lesson Objectives

By the end of this lesson, learners should be able to:

  1. Define haemophilia and differentiate between types A, B, and C.

  2. Describe the genetic inheritance patterns and prevalence of haemophilia in Zambia.

  3. Recognize the clinical signs and symptoms of haemophilia in children.

  4. Identify appropriate investigations to confirm diagnosis.

  5. Classify haemophilia severity and apply standard treatment protocols.

  6. Manage bleeding episodes with factor replacement, supportive care, and adjunct therapy.

  7. Provide guidance on vaccination, surgery, and routine follow-up for children with haemophilia.

Description

Haemophilia refers to inherited bleeding disorders caused by deficiency of specific coagulation factors. Haemophilia A results from factor VIII deficiency, haemophilia B from factor IX deficiency, and haemophilia C from factor XI deficiency. Haemophilia A and B are X-linked recessive; males are affected, females are carriers. Both conditions present similarly, requiring factor assays for precise diagnosis. Haemophilia C is autosomal and uncommon in Zambia.

Signs and Symptoms

Clinical Feature
Spontaneous or provoked bleeding
Large or deep bruises
Joint pain and swelling (hemarthrosis)
Excessive bleeding post-injury/surgery
Easy bruising
Menorrhagia
Nose bleeds
Unexplained bleeding, haematuria, haematochezia
Intracranial haemorrhage

Investigations

Test Finding
APTT Prolonged
PT Normal
Platelet count Normal
Factor assay Confirms deficiency of Factor VIII or IX

Classification of Haemophilia

Severity Factor Level
Severe <1%
Moderate 1–4%
Mild 5–40%

Normal factor level: 50–200%
Recommended weekly prophylaxis: 25–40 IU/kg or more depending on clinical situation.

Sites of Bleeding

Non-life or Non-limb-threatening Life- or Organ-threatening
Joints Intracranial
Muscles Muscle compartment
Easy bruising Neck/throat
Mucosal bleeding (epistaxis, gingiva) Massive gastrointestinal
Gastrointestinal Genitourinary tract

Factor Replacement Therapy

Factor VIII (Haemophilia A)

Indication Dose Notes
Minor acute bleed 30 units/kg 1 unit/kg increases FVIII by 2%
Major acute bleed 50 units/kg Half-life 8–12 hrs; may need 8–12 hr dosing
Follow-up As per paediatric haematology plan Round up to nearest vial

Factor IX (Haemophilia B)

Indication Dose Notes
Minor acute bleed 50 units/kg 1 unit/kg increases FIX by 1%
Major acute bleed 100 units/kg Half-life 18–24 hrs; may need ≥24 hr dosing
Follow-up As per paediatric haematology plan Round up to nearest vial

If factors unavailable: Order Fresh Frozen Plasma (10–20 mL/kg IV over 1 hr).

Supportive Care (PRICE)

  • Protection

  • Rest/Replacement

  • Ice/Immobilization

  • Compression

  • Elevation

Adjunct Therapy: Tranexamic acid 10 mg/kg IV every 8 hours or 15–25 mg/kg orally for mucocutaneous bleeding. Contraindicated in urinary tract bleeds.

Pain Management

  • Causes: joint capsular stretching, haemophilic arthropathy, compartment syndrome

  • Goals: relieve pain without increasing bleeding risk, improve quality of life

  • Preferred: COX-2 inhibitors such as tramadol

  • Avoid: aspirin, antiplatelet agents, intramuscular injections

Vaccination and Surgery

  • Vaccines: standard pediatric vaccines without prophylactic factor cover

  • Apply ice for 5 min before injection, smallest gauge needle (25–27G), 10 min pressure after

  • Irritant vaccines (e.g., tetanus) require prophylactic clotting factor cover

  • Surgery: discuss with paediatric haematologist, elective or emergency

Routine Follow-up

Age Visit Frequency Laboratory Tests Additional Checks
0–6 years Every 3 months Blood group (first visit), FBC, diff, retic count each visit, serum ferritin annually, Hep B/C/HIV serology annually HJHS annually, emergency preparedness, vaccination check, haemophilia counselling
6–16 years Every 6 months Blood group (first visit), FBC, diff, retic count each visit, Hep B/HIV serology annually, serum ferritin annually HJHS annually, assess readiness for self-infusion, emergency preparedness, begin transition assessments at 12 years

 

Bookmark